The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.
In older adults with diabetes, GLP-1 receptor agonists were tied to a slightly lower risk for depression compared with one ...
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...
Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...
Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...